Stockwinners Market Radar for June 13, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:37 EDT BBX Capital enters into settlement deal with Bass Pro - Bluegreen Vacations Corporation and its subsidiaries announced that Bass Pro Inc. and its affiliates and Bluegreen have settled their prior disputes and have amended their Marketing and Promotions Agreement that will reinstate Bluegreen's access to Bass Pro's marketing channels, including all marketing activities in Bass Pro retail stores and extend into the Cabela's retail stores. The parties have entered into a Settlement Agreement and Amendment which provides that: Bluegreen will pay Bass Pro the following amounts as a settlement of all prior claims, with no admission of wrongdoing: $20M within 15 days of the execution of the Settlement and Amendment; $4M each January 1st starting in 2020 through 2024; and Bass Pro will keep the remaining $1.5M of an amount prepaid to them earlier in 2019 under the Marketing and Promotions Agreement.

18:57 EDT DexCom CEO: There is plenty of room for us to grow over the long term - In an interview on CNBC's Mad Money, DexCom (DXCM) CEO Kevin Sayer said: Our vision in diabetes care can really come to fruition... We always have something in the works... We have several upgrades to our G6 system due out over the next year... We're moving our call centers to the Philippines... We currently have several digital initiatives with Walgreens (WBA)... We love our business and run it to be independent.

18:42 EDT Verint director Moriah sells 16.3K shares of common stock - In a regulatory filing, Verint disclosed that the President of its Customer Engagement Solutions division Elan Moriah sold 16.3K shares of common stock on June 11th-June 13th. The total transaction size was over $920K.

18:15 EDT Third Point confirms $1.5B investment in Sony - In a letter to shareholders, Third Point states: "Third Point has invested $1.5B in Sony Corporation because we believe it is one of the most undervalued large cap businesses in the world today. Sony's valuation does not reflect either the quality of the Company's businesses or the opportunity to create meaningful, long-term value through targeted capital allocation and further operational improvement. We rarely find companies like Sony that have a depressed valuation, high-quality underlying businesses, numerous options for portfolio optimization, and a capable management team. These conditions are reminiscent of our 2017 investment in Nestle.1 Over the past two years, we have provided constructive input to Nestle's CEO Mark Schneider and the Board, during which time the company has improved organic sales growth and operating margins, returned CHF 20 billion of capital to shareholders via buybacks, upgraded its Board, and focused its portfolio by divesting non-core assets, recycling the proceeds into high-quality acquisitions. Today, we see a similar opportunity to unlock value in Sony, a company we know well. Now that Sony is on a better path operationally, we believe CEO Yoshida-san has an opportunity to create a "Stronger Sony" by shifting his focus to unlocking the value of the Company's tremendous portfolio of assets. With the stock trading today at just 11x 2020 EPS, we see compelling upside from current levels catalyzed by a deliberate portfolio review, focused capital allocation, and strategic reorganization. There are many paths to unlock Sony's value. Sony has a net cash balance sheet, generates a 7% unlevered FCF yield, and owns stakes in publicly-listed companies totaling over $12 billion. This opportunity set is staggering: if management were to monetize these stakes and take leverage to a conservative 1.0x, the company would have $34 billion of capital to invest for growth or return to shareholders, equal to more than 50% of the current market capitalization. Encouragingly, it appears Sony management shares our view. In February, the company announced a 100 billion share repurchase, its first buyback in 15 years. This was followed by an additional 200 billion repurchase announcement in May. Today, Sony trades at roughly half our estimate of intrinsic value, with additional upside from optimizing capital allocation. In order to release this value and put the Company on an even stronger footing for the future, we believe that Sony should: 1) consider a spin-off of its semiconductors division into a standalone public stock, re-named "Sony Technologies", to be listed in Japan; 2) position New Sony as a leading global entertainment company; 3) consider the divestiture of its public equity stakes in Sony Financial, M3 Inc, Olympus, and Spotify, and; 4) optimize its capital structure. We make these recommendations with Sony's long-term success at the forefront of our considerations and believe these actions will help Sony to more effectively and sustainably grow value for stakeholders in the decades to come."

17:31 EDT Gladstone Land buys 542 acre farm land parcel in California for $9.2M - Gladstone Land announced that it has acquired 542 gross acres of farmland in Yolo County, California, for approximately $9.2 million. The farm includes a 482-acre, high-density olive orchard. In connection with the acquisition, the company also entered into a 15-year, triple-net lease with the seller, California Olive Ranch, Inc., reported to be the largest extra virgin olive oil producer in the U.S.

17:18 EDT Ross Stores CEO sells 40K shares of common stock - In a regulatory filing, Ross Stores disclosed that its CEO Barbara Rentler sold 40K shares of common stock on June 12th and June 13th. The total transaction size was $3.97M.

16:53 EDT Verso to explore strategic alternatives - Verso announced that its board had in late March of 2019, reengaged Houlihan Lokey Capital, Inc. as the company's financial advisor to assist Verso in identifying and evaluating a range of potential strategic alternatives, including a possible merger, joint venture, partnership, business combination, stock repurchase, recapitalization, sale, distribution, transfer or other disposition or acquisition of assets or equity interests, while the company conducts its search to identify and retain a permanent chief executive officer. The company also announced that the board has approved the adoption of a limited duration stockholder rights plan and authorized a dividend distribution of one right for each outstanding share of common stock, subject to the board's approval of final documentation.

16:42 EDT Omega Flex raises quarterly dividend to 28c from 24c per share - The dividend is payable on July 2, 2019 to shareholders of record on June 24, 2019.

16:36 EDT Bristol-Myers announces data from Phase 4 Orencia study at EULAR - Bristol-Myers announced data from a Phase 4 mechanistic study exploring differences in the cellular and molecular mechanisms by which Orencia and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis, or RA, patients seropositive for certain autoantibodies. These results, which are from a prospective analysis of the Early AMPLE head-to-head trial, are featured in a late-breaking oral presentation at the European Congress of Rheumatology, or EULAR. Among 80 adult patients with early moderate-to-severe RA who had never been treated with a biologic medication and tested positive for autoantibodies called anti-citrullinated protein antibody, or ACPA, and rheumatoid factor, or RF, numerically higher efficacy responses were seen with Orencia at week 24. ACR 20/50/70 responses with Orencia were 83, 70 and 48 respectively; ACR 20/50/70 scores for adalimumab were 63, 45 and 30, respectively. Higher responses were observed in patients with a well-known genetic marker of RA prognosis called the "Shared Epitope", or SE. In SE+ patients, numerically greater efficacy was observed with Orencia. Patients in both arms of the study were also treated with stable, oral methotrexate, or MTX, weekly. Rheumatoid factor and ACPA are biomarkers associated with a more severe disease course in RA. The HLA-DRB1 allele, which codes for SE, provides instructions for making a protein that plays a key role in helping the immune system distinguish one's own proteins from those of harmful invaders, such as bacteria and viruses. Shared Epitope has been shown to be strongly associated with RA and is thought to be involved with the continuous activation of immune cells, called T cells, that characterizes RA. Shared Epitope is present in 70%-80% of RA patients positive for ACPA. Similar numbers of related adverse events and related serious adverse events were observed in the two treatment arms. The overall safety profile of Orencia was consistent with prior studies, with no new safety signals identified.

16:34 EDT Ensco Rowan discloses capital structure proposal from Luminus Management - The Ensco Rowa board disclose that it received a proposal from Luminus Management dated June 12, 2019, stating that it "welcomes investor perspectives on matters such as the company's capital structure and the return of capital to shareholders, and will evaluate the proposal. The company has significant financial flexibility within its capital structure, including the ability to issue debt that would be structurally senior to the company's currently outstanding debt on both an unsecured and secured basis."

16:33 EDT Univar Solutions named distributor of Seaweed & Co. - Europe, Univar B.V., a subsidiary of Univar Inc., announced that Seaweed & Co. has selected Univar Solutions to distribute its PureSea range of seaweed ingredient products into the food industry across selected countries throughout Europe. The product range brings flavour and health benefits to a wide range of food and beverage applications. "We are very pleased to add Seaweed & Co. as a strategic supplier for our food ingredients market as this presents tremendous opportunity to drive new growth through organic, natural and sustainably sourced products," said Gary Abraham, head of supplier management in Europe, Middle East and Africa for Univar Solutions. "The PureSea portfolio enables us to enhance our solutions-based offering for our customers and meet emerging demand for seaweed ingredient products."

16:31 EDT W.P. Carey raises quarterly dividend to $1.034 from $1.032 per share - The dividend is payable on July 15, 2019 to stockholders of record as of June 28, 2019.

16:28 EDT Broadcom reports Q2 adjusted gross margin 72% vs. 66.6% a year ago - Gross margin from continuing operations was 72% of net revenue. This compares with gross margin from continuing operations of 71.4% of net revenue, in the prior quarter, and 66.6% of net revenue, in the same quarter last year.

16:25 EDT Enstar Group John Hendrickson buys over $1M in company shares - Enstar Group officer John Hendrickson disclosed in a filing that he had purchased 6,000 shares of company stock at an average price of $172.50 per share on June 12. The total transaction value of the purchase was $1,035,000.

16:23 EDT Broadcom reports Q2 gross margin 56% vs. 50.9% a year ago - Gross margin was 56% of net revenue. This compares with gross margin of 55.4% of net revenue, in the prior quarter, and gross margin of 50.9% of net revenue, in the same quarter last year.

16:21 EDT Iqvia OCE technology platform selected by Ferring Pharmaceuticals - Iqvia announced that Ferring Pharmaceuticals has selected Iqvia Technologies' orchestrated customer engagement, or OCE, platform for global deployment across more than 50 markets. Iqvia Technologies' OCE for customer engagement breaks down silos by connecting sales, account management and other functions to drive performance.

16:19 EDT Broadcom CEO says 'we see a broad-based slowdown in the demand environment' - "We executed according to plan in the second quarter with tailwinds from networking offsetting the anticipated headwinds from wireless," said Hock Tan, President and CEO of Broadcom. "We currently see a broad-based slowdown in the demand environment, which we believe is driven by continued geopolitical uncertainties, as well as the effects of export restrictions on one of our largest customers. As a result, our customers are actively reducing their inventory levels, and we are taking a conservative stance for the rest of the year. We remain well-positioned across our various semiconductor and software businesses and are confident this portfolio of franchises will continue to drive sustained long-term revenue growth and increasing free cash flow." "We achieved record free cash flow of $2.5 billion growing 20% year over year in the second quarter," said Tom Krause, CFO of Broadcom Inc. "Despite the challenging market backdrop and updated revenue outlook, we still expect to grow free cash flow by a double-digit percentage for the year. In addition, we remain focused on completing a total of $8 billion of share repurchases and eliminations in fiscal 2019."

16:18 EDT Cherry Hill Mortgage names Michael Hutchby CFO - Cherry Hill Mortgage Investment Corporation announced the promotion of Michael Hutchby to Chief Financial Officer, from Controller, effective immediately. Hutchby succeeds Martin Levine, who will remain in his role as President of Aurora Financial Group, Inc., Cherry Hill's wholly-owned mortgage servicing subsidiary. Hutchby will report directly to Jay Lown, President and Chief Executive Officer. "Marty has been a valuable contributor to Cherry Hill, playing a vital role in growing our business since our initial public offering six years ago. The Board and I extend our sincerest gratitude to Marty for all of his efforts as CFO, and know as President of Aurora that he will continue to be an important member of the team," said Mr. Lown. "Concurrently, we are pleased to promote Mike to CFO. He has also been an instrumental part of our team since the IPO, and his deep experience, extensive knowledge of our business and the industry made him the natural candidate to succeed Marty as we continue to grow Cherry Hill."

16:17 EDT Mexico authorizes Citi to deregister stock from Mexican Securities Registry - On June 3, 2019, the Mexican Banking and Securities Commission authorized Citigroup Inc. to deregister its common stock from the Mexican Securities Registry and delist from the Mexican Stock Exchange, effective at the end of the trading day on July 10, 2019. The deregistration is conditional upon the cross-listing of the common stock on the International Quotation System managed by the Mexican Stock Exchange, which is expected to occur on July 11, 2019. Citigroup's common stock will begin trading on the International Quotation System at its New York Stock Exchange closing price on July 10, 2019. Trades of Citigroup common stock currently listed on the Mexican Stock Exchange executed on July 9, 2019 will settle within 24 hours, and trades executed on July 10, 2019 will settle on the same day. The delisting of Citigroup's common stock from the Mexican Stock Exchange and its cross-listing on the International Quotation System managed by the Mexican Stock Exchange, will not affect Citigroup's businesses in Mexico. Mexico is an important market for Citigroup, which is committed to further strengthening its capabilities to better serve its institutional and consumer clients in the country.

16:11 EDT Louisiana-Pacific to curtail OSB production at British Columbia facility in Q3 - Louisiana-Pacific announced that its Peace Valley facility in Fort St. John, British Columbia, will indefinitely curtail production of oriented strand board, or OSB, beginning early in Q3. The Peace Valley OSB mill currently employs approximately 190 people. It has a stated annual capacity of 800 million square feet.

16:07 EDT Four Corners Property Trust acquires Carrabba's Italian Grill property for $2.2M - Four Corners Property Trust (FCPT) announced the acquisition of a Carrabba's Italian Grill property for $2.2M. The property is located in Florida and is leased to the corporate operator under a triple-net lease with approximately 3.5 years of term remaining. Carrabba's has 226 domestic locations and is a subsidiary of Bloomin' Brands (BLMN), which is also the owner of the Outback Steakhouse, Bonefish Grill and Fleming's Steakhouse brands. The transaction was priced at a 7.3% going-in cash cap rate, exclusive of transaction costs.

16:03 EDT Kezar Life Sciences announces 'promising' data in KZR-616 study - Kezar Life Sciences announced positive results from the Phase 1b open-label dose escalation portion of the MISSION study evaluating KZR-616 in patients with systemic lupus erythematosus. The primary objective of this first-in-patient study is to assess the safety and tolerability of KZR-616. Secondary objectives of the study include evaluating pharmacokinetics and determining doses for the Phase 2 portion of the study. As of the data cutoff date of May 6, 2019, the Phase 1b portion enrolled 24 SLE patients with a median SLEDAI score of 10 across three cohorts. Weekly subcutaneous administration of KZR-616 at both 45 mg and at 60 mg appeared to be well tolerated and demonstrated rapid and broad immunomodulatory activity as consistently evidenced by positive efficacy data across multiple measures of disease activity, including patient reported outcomes. Consistent PD was seen between 45 mg and 60 mg step-up with target levels of immunoproteasome inhibition achieved. Patients receiving KZR-616 did not experience the hematologic or constitutional toxicities associated with approved non-specific proteasome inhibitors. The favorable safety profile of KZR-616 supports the dose levels for the Phase 2 portion of the MISSION study.

16:03 EDT Apollo Endosurgery announces U.S. labeling update for Orbera - Apollo Endosurgery, Inc. announced that it has received FDA approval for its proposed labeling updates for the ORBERA Intragastric Balloon System. The goal of the labeling updates is to improve patient safety and these will take effect immediately. The labeling updates improve patient safety by providing further definition and guidance on the appropriate use of the ORBERA Intragastric Balloon System and patient selection. The most notable safety labeling updates included: Clarification to contraindications. These changes clarified that the previous "hepatic insufficiency or cirrhosis" contraindication related to patients with acute liver failure and decompensated cirrhosis. The changes also clarified the types of previous gastric surgery that are contraindications; Added precautions related to patients who are taking anti-cholinergic or psychotropic medications that are known to delay gastric emptying; Updated US adverse event tables based on the current market surveillance data. There were no new categories of adverse events added and occurrence rates did not materially change; Other procedure technique-related edits were made to the instructions for use.

15:44 EDT Mattel not worth more than $6 per share, MGA CEO says - Speaking on CNBC, MGA Entertainment CEO Isaac Larian said that Mattel is not worth over $6 per share. The stock, which was up prior to his interview, has moved lower to trade near $11.36 per share. Earlier this week, Larian stated in an interview with the Los Angeles Times that Mattel had rejected another unsolicited offer by his company last month.

15:28 EDT Atlas Air says subsidiary prevailed in arbitration against pilots union - Atlas Air Worldwide Holdings confirmed that its subsidiary, Southern Air, has prevailed in an "important" arbitration against the union that represents Southern Air's pilots, the Airline Professionals Association, Teamsters Local 1224. The June 12 arbitration decision orders the union to promptly proceed with contractually required negotiations for a new joint collective bargaining agreement in connection with the merger of Southern Air and Atlas Air, the company said. The decision states that "We can conclude with some certainty, however, that there has been a delay inspired by the Union's misapprehension of the contractual requirements and that they must now respond vigorously to the company's request to proceed," the company said.

14:41 EDT Facebook makes investment in in Indian e-commerce start-up Meesho - Meesho said in a blog posting on its website: "Today is an exciting day for Meesho! We'd like to announce that Facebook has made an investment in Meesho, which will help us further our efforts to enable independent entrepreneurs to build businesses and grow their customer base via social channels. It has been an amazing journey for us and we cannot wait to do more, as we work towards our goal of building a bigger community and enabling millions of entrepreneurs to be successful. Over the last 4 years we've grown from our humble beginnings, to a community of more than 15,000 suppliers and 2,000,000 resellers throughout India. We share a common goal with Facebook - to enable the community and help small businesses grow. We'd like to thank our entrepreneur community, investors, and everyone who has had faith in us from the beginning - we can't wait to keep building." Reference Link

14:25 EDT Red Robin says open to Vintage participation in search for 'world-class CEO'

14:19 EDT U.S. Secretary of State says Iran responsible for tanker attacks - U.S. Secretary of State Mike Pompeo is speaking at a press conference about the attacks on two oil tankers in the Gulf of Oman.

14:04 EDT Avista Chairman Scott Morris sells over $1M in company shares - Avista Chairman Scott Morris disclosed in a regulatory filing that he had sold 23,000 shares of company stock at $44.33 per share on June 13. The total transaction value of the sale was $1,019,505.

13:55 EDT DOJ settles with First Merchants over lending discrimination - The Department of Justice and the U.S. Attorney's Office for the Southern District of Indiana filed a complaint and settlement agreement, resolving allegations that First Merchants Bank engaged in lending discrimination by "redlining" predominantly African-American neighborhoods within Indianapolis, Indiana. "Redlining" is a term describing an illegal practice in which lenders intentionally avoid providing services to individuals living in predominantly minority neighborhoods because of the race of the residents in those neighborhoods, the DOJ noted. Under the settlement agreement, which is subject to court approval, First Merchants will expand its marketing efforts, lending, and banking services to specifically include predominantly African-American neighborhoods in Indianapolis. To remedy the harm to those living in the redlined areas, the Bank will invest $1.12M in a loan subsidy fund to increase credit opportunities to residents of predominantly African-American neighborhoods, and will devote $500,000 toward advertising, community outreach, and credit repair and education. The Bank will also open a branch and loan production office to serve the banking and credit needs of residents in predominantly African-American neighborhoods in Indianapolis.

13:44 EDT Kirkland's director Charles Pleas buys 100K shares of company stock - Kirkland's director Charles Pleas disclosed in a filing that he had purchased 100,000 shares of company stock at an average price of $2.39 per share on June 12. The total transaction value of the purchase was $239,000.

13:17 EDT Morrisons, Amazon expand 'Morrisons at Amazon' store on Prime Now - WM Morrison (MRWSY) and Amazon (AMZN) announced they are expanding the 'Morrisons at Amazon' store on Prime Now to many more cities across the U.K. 'Morrisons at Amazon' is a same day, online grocery home delivery service, currently available to Amazon Prime Now customers in four cities: Leeds, Manchester, Birmingham, and parts of London and the home counties. Customers can order a full Morrisons shop online, which is then picked at a local Morrisons store, and delivered by Amazon. The option for delivery within one hour of the order being placed is available for many customers across these cities. During 2019, this ultra-fast same day service will begin to be rolled out to other cities, including Glasgow, Newcastle, Liverpool, Sheffield and Portsmouth. In future years, 'Morrisons at Amazon' will be expanded to further cities across the UK. The expansion will see Morrisons becoming a retailer on Amazon's Prime Now website and app, through 'Morrisons at Amazon', and selling directly to customers. Morrisons will continue as a wholesaler for all Amazon's other UK grocery offers for customers.

12:54 EDT Twitter says deleted thousands of accounts tied to Iran - Twitter said in a blog post that it removed thousands of accounts linked to coordinated, state-backed activities it believes were from the Iranian government and archived them to its public database launched last year, saying "Since its launch, thousands of researchers from across the globe have downloaded datasets, which contain more than 30 million Tweets and over 1 terabyte of media, using our archive to conduct their own investigations and to share their insights and independent analysis with the world." In the latest purge of information, the company said it believes 4,779 accounts were associated or backed by Iran. It added: "As part of our ongoing investigations into activity connected with the Russian Internet Research Agency, we removed four accounts which we believe are associated with the IRA. These removals are the result of increased information sharing between industry peers and law enforcement." Reference Link

12:06 EDT NXP Semiconductors developing UWB technology for various markets - NXP Semiconductors announced at its annual developer conference in the Silicon Valley its development of UWB technology designed for a broad range of markets, including mobile, automotive, Internet-of-Things and industrial. NXP's new UWB technology brings secure ranging and precision sensing creating a new dimension of spatial context for wireless devices. This strategic announcement sets the stage for UWB-enabled use cases likely to emerge in the market as soon as 2020. "NXP's UWB sparks exciting new use cases that have never before been possible," said Kurt Sievers, President at NXP. "The technology not only understands motion and relative positioning outdoors and indoors, but its real-time robust accuracy can change the way we drive efficiency in factories, play interactive games or use AR/AI applications on our phones. We're excited to share news of our our latest developments in this space to bring us into a new era of intuitive on-demand applications."

12:00 EDT Pacific Drilling falls -7.6% - Pacific Drilling is down -7.6%, or -98c to $11.98.

12:00 EDT Cooper-Standard falls -9.0% - Cooper-Standard is down -9.0%, or -$3.77 to $38.12.

12:00 EDT Summit Materials rises 17.1% - Summit Materials is up 17.1%, or $2.33 to $16.02.

11:34 EDT Materialise reports FDA clearance for cardiovascular planning software - Materialise announced that it has received FDA clearance for its Mimics Enlight cardiovascular planning software suite. The first release will support clinicians planning complex transcatheter mitral valve replacement procedures, the company said. Bryan Crutchfield, vice president and general manager of Materialise North America, said, "We work very closely with teams at our partner hospitals and medical device companies to identify areas where 3D planning and printing can improve their ability to plan procedures. With the FDA clearance of Mimics Enlight, we are expanding the 3D toolkit for cardiologists working to treat patients with complex cardiovascular issues, starting with mitral valve replacement."

11:22 EDT Dan Niles says Netflix shares should go down more on Disney launch - Dan Niles of AlphaOne Capital Partners is speaking on CNBC.

11:17 EDT Wells Fargo names Debra Chrapaty CTO - Wells Fargo named Debra Chrapaty as chief technology officer, making permanent a role she held on an interim basis since May. She will continue reporting directly to Saul Van Beurden, head of Technology at Wells Fargo. Chrapaty will lead Wells Fargo's technology transformation, accelerating all efforts to enhance the developer experience by cloud-enablement, full CI/CD automation and Agile way of working. In addition, Chrapaty will run platform services and enterprise architecture.

10:55 EDT Fiverr CEO says online freelancing opportunity 'massive' - Kaufman said freelancing is still a "very old school business" and he sees the opportunity to move freelancing to online being "massive." Kaufman sees using proceeds from IPO for working capital and to fuel growth, he said. Fiverr CEO Micha Kaufman is being interviewed on CNBC following the company's IPO this morning.

10:11 EDT Jana Partners discloses 9.5% activist stake in Callaway, may push for sale - Jana Partners this morning disclosed a 9.5% stake in Callaway Golf, which represents over 8.9M shares. The filing allows for activism. Shares of Callaway Golf are up 14%, or $2.26, to $18.15 in early trading. Jana said it acquired the shares because they believe the stock is "undervalued and represent an attractive investment opportunity." Jana believes that, despite the success of Callaway in "driving innovation and durable market share gains in its core golf business," other factors have caused the company to "underperform and remain undervalued." Jana intends to have discussions with Callaway's board and management regarding portfolio composition, strategic alternatives, including exploring a sale of the company or asset divestitures, capital allocation and acquisition strategy, as well as cost management and governance. Jana said that it may also, potentially with the assistance of other shareholders, "take other steps to increase shareholder value."

10:00 EDT Cooper-Standard falls -9.6% - Cooper-Standard is down -9.6%, or -$4.03 to $37.86.

10:00 EDT Frontline rises 10.7% - Frontline is up 10.7%, or 77c to $7.99.

10:00 EDT RH rises 22.3% - RH is up 22.3%, or $21.18 to $116.08.

09:47 EDT Scor ADR falls -7.6% - Scor ADR is down -7.6%, or -$1.69 to $20.51.

09:47 EDT Callaway Golf rises 10.8% - Callaway Golf is up 10.8%, or $1.72 to $17.62.

09:47 EDT RH rises 25.4% - RH is up 25.4%, or $24.11 to $119.00.

09:27 EDT Tyler Technologies signs agreement with Yolo Superior Court, California - Tyler Technologies announced that it has signed an agreement with the Yolo Superior Court, California, for Tyler's Odyssey Case Manager, Odyssey File & Serve electronic filing, and Modria online dispute resolution solutions. The Yolo Superior Court determined that its current vendor was no longer meeting the court's evolving needs for court case management. The court selected Tyler because of its well-known court case management presence, maturity, and experience specifically in California.

09:16 EDT Sequential Brands announces new category expansion for GAIAM brand - Sequential Brands Group announced that it has signed a partnership for GAIAM-the yoga, fitness and wellness brand-to expand the brand into the growing natural personal care and wellness space. A line of GAIAM branded specialty bath and personal care products is expected to launch next year and be available online and at retailers nationwide. The aromatherapy driven line will consist of pure essential oils and feature scents that refresh.

09:13 EDT BioScrip says John Rademacher to be CEO following close of Option Care merger - BioScrip announced that key members of BioScrip's leadership team will continue in executive roles with the combined company following the close of its pending merger with Option Care Enterprises. Dan Greenleaf, president and CEO of BioScrip, will become Special Advisor to the newly combined company's board Chairman, Harry Kraemer, and CEO John Rademacher. Greenleaf will provide strategic and operational counsel to ensure a smooth transition, optimize the integration of both companies, and drive long-term growth opportunities. In addition, other members of BioScrip's existing senior leadership team will continue with the combined company in key executive roles following the merger close, including: Harriet Booker, who will continue as COO; Rich Denness, who will become CSO; John McMahon, who will become SVP Corporate Finance; Bob Roose, who will continue as SVP, Procurement; and Arcot Prakash, who will become VP Information Technology.

09:10 EDT Lightbridge awarded new patent related to metallic fuel rod across Eurasia - Lightbridge Corporation announced that it has received a Notice of Allowance for a new patent related to its innovative metallic fuel rod and fuel assembly design in countries that are signatories to the Eurasian Patent Convention. These countries include Russia, Kazakhstan, Belarus, Azerbaijan, Armenia, Turkmenistan, Tajikistan, Kyrgyz Republic, and Republic of Moldova. The new patent is based on Lightbridge's 2014 Patent Cooperation Treaty application and covers an alternative embodiment of a multi-lobe fuel rod design; an all-metal pressurized water reactor fuel assembly design incorporating multi-lobe fuel rods based on the alternative embodiment.

09:08 EDT Mondelez invests $6M in Reading Science Centre in the UK - Mondelez International announced today it is investing $6 million in its Reading Science Centre in the UK to support the development of new chocolate, biscuit and candy products, serving over 150 different countries. The Reading Science Centre is currently home to over 290 scientists, chemists, food technologists and other specialists. The new investment will result in the creation of 50 highly skilled food science and engineering jobs over the next five years. The new Reading investment comes on top of the company's previously announced global investment of $65M in its eleven technical centers around the world.

09:06 EDT On Track Innovations receives new order for 1,000 payment systems in Japan - On Track Innovations received a purchase order for 1,000 cashless payment systems from Japan via its partner, Billing Systems Cooperation, a regional payment service provider. The systems ordered included OTI's UNO Plus EMVco and FeliCa contactless reader as well as the GoBox Multi-Service Telemetry Gateway.

09:03 EDT CenturyLink expands in new Miami network gateway - CenturyLink is making a significant investment to expand its network in the South Florida market. Located in Miami, the new facility aims to also help the company serve the demand for enterprise services in Latin America, as well as from South Florida organizations doing business there. The expansion includes a new network gateway, to manage the flow of internet and data traffic on CenturyLink's global network, and a data center. Initial design began in May, and construction is anticipated to begin in September. CenturyLink expects to begin moving infrastructure into the building in summer 2020.

09:02 EDT Eastside receives first distributor order for 'Outlandish' CBD beverages - Eastside Distilling announced it has received its first purchase order for its all-new Outlandish CBD-based beverage. "The initial order of the Outlandish 24-pack format, targeted for "on premise" sale and consumption, was placed by Point Blank Distributing for the Outlandish CBD Seltzer and will be sold only in Oregon. The 24-pack is specifically designed for bars, restaurants and other accounts that already sell large volumes of seltzer and other mixer products to their patrons and is intended to expose Outlandish to as many consumers as soon as possible."

08:54 EDT Elizabethtown Gas to implement $300M infrastructure investment program - The New Jersey Board of Public Utilities has authorized Elizabethtown Gas, a subsidiary of SJI, to implement a $300M, five-year infrastructure investment program . Commencing July 1, the IIP will begin the replacement of approximately 250 miles of vintage cast iron and bare steel mains and related services, as well as the installation of excess flow valves on new service lines. There is no proposed impact to customer bills at this time.

08:52 EDT Silk Road says TCAR achieves favorable outcomes vs. carotid endarterectomy - Silk Road Medical announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting. In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization Surveillance Project. The presentation, "Outcomes of Transcarotid Revascularization with Dynamic Flow Reversal Versus Carotid Endarterectomy in the Transcarotid Revascularization Surveillance Project," evaluated patients between 2015 and 2018, with 5,716 patients receiving TCAR compared to 44,442 patients receiving carotid endarterectomy with 5,160 patients in each group analyzed using propensity score matching. There were no statistical differences noted between TCAR and CEA for in-hospital stroke or in-hospital stroke and death. Other key findings for TCAR compared to CEA include: 59% lower odds of in-hospital myocardial infarction; 87% lower odds of in-hospital cranial nerve injury; 35% lower odds of in-hospital stroke, death and myocardial infarction; 26% lower odds of hospital stay longer than 1 day; 25% lower odds of non-home discharge; In a separate risk adjusted analysis looking at 30-day and 1 year follow up, the results were as follows: 34% lower odds of 30-day death; 46% lower odds of 30-day stroke and death; 53% lower odds of 30-day stroke, death and MI; 23% lower odds of 1-year mortality.

08:48 EDT Amarantus Bioscience issued U.S. patent covering MANF treatment - Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued U.S. Patent No. 10,195,251 entitled 'Methods of Treatment for Retinal Diseases Using MANF and CDNF' that covers the use of mesencephalic astrocyte-derived neurotrophic factor or cerebral dopamine neurotrophic factor as a treatment for various ophthalmic disorders, including inherited retinal disorders, age-related macular degeneration and glaucoma. The approved claims cover the use of MANF or CDNF as an eye drop, as well as intravitreal injection. MANF Therapeutics is focused on the development of MANF as an intravitreal injection for the treatment of Wolfram's Syndrome and Glaucoma.

08:44 EDT CHF Solutions says AATS session highlighted benefits of Aquadex FlexFlow use - CHF Solutions announced highlights from the sponsored session from the American Association for Thoracic Surgery Annual Meeting. The panel, titled "Personalized Medicine: Improving Clinical Outcomes with Novel Fluid Management Strategies," highlighted a discussion on the use of the Aquadex FlexFlow system to help manage risks associated with fluid overload in adult cardiac surgery patients. Among the key reasons cited for using the device were the ease of use for both doctors and other hospital staff, rapid patient recovery, decrease in mortality, efficient utilization of hospital resources, and the ability to personalize treatment based on the individual patient's need.

08:39 EDT R2 Dermatology announces China/Asia-Pacific distribution agreement with Huadong - R2 Dermatology announced that it has entered into an exclusive distribution agreement with China's Huadong Medicine Company Limited for the Asia-Pacific Region. In exchange, Huadong will make an equity investment in R2 Dermatology to fund R2's next phase of product and market development.

08:35 EDT Progenics doses first patient in Phase 2 clinical study of 1095 radiotherapy - Progenics Pharmaceuticals announced that the first patient has been dosed in the Company's Phase 2 clinical study evaluating I-131 1095 radiotherapy in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer. 1095 is the Company's small molecule radiotherapeutic designed to selectively bind to the extracellular domain of prostate specific membrane antigen. The multicenter, randomized, open-label, controlled Phase 2 clinical study is evaluating the efficacy and safety of 1095 in combination with enzalutamide compared to enzalutamide alone in patients with mCRPC who are PSMA-avid, chemotherapy naive, and progressed on abiraterone. PSMA-avidity is determined utilizing PyL, the Company's PET imaging agent in clinical development designed to visualize prostate cancer. The trial is expected to enroll approximately 120 patients at 25 sites in the U.S. and Canada. The study's primary endpoint is prostate specific antigen response rate according to Prostate Cancer Clinical Trials Working Group 3 criteria defined as a confirmed 50% or greater decline from baseline. Key secondary endpoints evaluate radiographic response based on Response Evaluation Criteria In Solid Tumors for soft tissue or PCWG3 for bone, progression free survival, and overall survival. Patients will be followed for one year after their first treatment for all efficacy endpoints. Survival and safety data will be collected for an additional year.

08:34 EDT Capstone Turbine executes additional 3.2 MWs of long-term service contracts - Capstone Turbine Corporation announced that E-Finity Distributed Generation, Capstone's exclusive distributor for the Mid-Atlantic, Southeastern United States and the Caribbean, signed Factory Protection Plan service contracts in the Marcellus and Utica shale regions in the Appalachian Basin covering 3.2 megawatts of Capstone microturbines.

08:32 EDT Spartan Motors purchases assets of California-based General Truck Body - Spartan Motors has purchased the assets of General Truck Body and will begin operating a production facility located in Montebello, California. Going forward, the facility will be used to manufacture and assemble custom aluminum and composite-side truck bodies, refrigerated trucks, stake body trucks, curtain side and moving vans, last mile delivery vehicles and upfits, and other Work Driven Design vocational solutions across GVWR Classes 1-7. GTB joins Spartan's Fleet Vehicles and Services business unit. It will go-to-market under the Utilimaster brand.

08:28 EDT Royale Energy, RMX Resources announce drilling of Sansinena Oil Field - Royale Energy and RMX Resources jointly announced the successful drilling and completion of the Sansinena 9B-18 and 9B-20 oil wells. The 9B-18 well was completed on June 4, 2019 and flowed at 360 barrels of oil per day and 432 MCF per day with a flowing tubing pressure of 730 psig during an initial 24-hour flow test. The well was subsequently shut in for pressure testing and will be placed back online later this week. The 9B-20 well was completed on June 7, 2019 and has been flowing steadily at a rate of 200 barrels of oil per day and 72 MCF per day. Royale Energy and its investors own 50% of both wells of which Royale owns approximately 41%. RMX Resources is the operator and owns the other 50% of the wells.

08:21 EDT Spero Therapeutics announces $10M registered direct offering of common stock - Spero Therapeutics announced that it has entered into a definitive agreement to sell up to $10,000,000 of Spero's common stock in a registered direct offering with Novo Holdings A/S to be issued in two tranches. The first tranche of the offering consists of 465,983 shares sold at a price of $10.73 per share, for aggregate gross proceeds to the Company of approximately $5,000,000, and is expected to close on or about June 14, 2019, subject to the satisfaction of customary closing conditions. The closing of the second tranche of $5,000,000 is triggered upon the earlier of Spero's public announcement of pharmacokinetic data from the lead-in cohort in its Phase 3 clinical trial of SPR994 and June 30, 2020. The number of shares to be sold in the second tranche will be determined by the volume weighted average trading price of Spero's common stock around the trigger date. Because the shares of common stock are being sold directly to Novo Holdings A/S and not through a placement agent, underwriter or securities broker or dealer, Spero is not paying any underwriting discounts, commissions, concessions or similar compensation with respect to the sale. Spero intends to use the net proceeds to advance its SPR720 program. SPR720 is Spero's oral antibiotic being developed for the treatment of non-tuberculous mycobacterial infections. In February 2019, SPR720 was granted Qualified Infectious Disease Product designation by the U.S. Food and Drug Administration for both the treatment of NTM infections and lung infections caused by non-tuberculous mycobacteria and Mycobacterium tuberculosis. The Novo REPAIR Fund focuses on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control, including TB. SPR720 is currently in a Phase 1 clinical trial in healthy volunteers, and Spero expects top-line data from the trial in the second half of 2019.

08:16 EDT Sanuwave Health announces second peer review article on diabetic foot ulcers - SANUWAVE Health announces the follow-on publication of the research that investigated the effects of dermaPACE extracorporeal shock wave technology compared with Standard of Care in the treatment of diabetic foot ulcers. The peer reviewed article, titled "Focused shockwave therapy in diabetic foot ulcers: secondary endpoints of two multicentre randomized controlled trials" has been published in the June 2019 issue of the Journal of Wound Care. This is the second peer reviewed article detailing the results of Phase III DFU trials using dermaPACE as the investigative device and is a follow-on to the first peer-reviewed article "Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre, prospective, controlled, double-blinded, randomised phase III clinical trials" by the same authors. This second peer reviewed article further details the results from the two Phase III clinical trials SANUWAVE sponsored to study the effects of dermaPACE System treatment on Diabetic Foot Ulcers in conjunction with standard of care as compared to standard of care alone. The two studies evaluated 336 patients; 172 patients treated with dermaPACE and 164 managed with a sham device. The demographic characteristics of patients in the two arms of both studies were balanced and statistical comparison of the two studies justified pooling datasets for analysis. While the first peer reviewed article discussed the study design and results of the primary objective of comparison of wound closure rates at 12 weeks between dermaPACE and Standard of Care, this paper discusses the secondary safety and efficacy outcomes. Highlights of the efficacy and safety outcomes are: the mean wound reduction for dermaPACE subjects was statistically significant compared to the control group from the 6 week follow-up visit through the end of the stud. dermaPACE closes wounds faster than standard of care. Beginning at week 4 and through to 24 weeks, the dermaPACE group has a higher percentage of subjects with a 50% wound reduction compared to the control. dermaPACE helps clinicians achieve of point of being more manageable than standard of care. The difference in the proportion of wounds achieving greater than 90% reduction was significantly higher in the dermaPACE group than in the control group. dermaPACE helps the patient get extremely close to full closure better than standard of care. The difference in time to wound closure between the active therapy and sham-treated groups was statistically significant in favor of the dermaPACE group. Approximately 25% of dermaPACE subjects achieved wound closure by 84 days, as compared to the same number in the control group reaching closure by 116 days. dermaPACE closed wounds one full month faster than standard of care. Rate of recurrence of closed ulcers was higher in the control group but not significant. dermaPACE provided a better wound closure than standard of care. The dermaPACE treatment was well tolerated by the subjects; there was no significant change in pain from SOC with only 1.2% of the dermaPACE subjects reporting procedural or application site pain vs. 1.8% in the control group. dermaPACE is less painful than standard of care.

08:10 EDT TransUnion announces creation of new Sustainability Office - TransUnion announced the creation of a Sustainability Office and issued the 2018 Corporate Social Responsibility Report. The Sustainability Office will engage a cross-functional working group, under the guidance of a steering committee made of members of the executive leadership team. Hilary Chidi will lead the Sustainability Office, in addition to his current role as senior vice president and head of product for Consumer Interactive.

08:08 EDT Alkaline Water adds Crossmark as national broker representative - The Alkaline Water Company announced that it has added Crossmark as one of its national broker representatives for the national convenience store channel. The company entered into an agreement with Crossmark to place its product portfolio, including its infused beverage line, into convenience store chains across the country.

08:07 EDT CPI Aerostructures receives $14M in additional orders from Sikorsky - CPI Aerostructures (CVU) announced that it has received purchase orders totaling approximately $14M from Sikorsky, a Lockheed Martin Company (LMT), for Hover Infrared Suppression System module assemblies for use as spares on older variants of the UH-60 Black Hawk helicopter. Deliveries under these orders will commence in 2020 and be completed in 2022. As previously disclosed, the company received purchase orders totaling approximately $8M in October 2018 for HIRSS systems from Sikorsky for the Black Hawk. Deliveries under the October 2018 orders will commence before the end of 2019 and continue into 2021.

08:05 EDT Dryships trading resumes

08:03 EDT Entasis Therapeutics announces initial ETX0282 Phase 1 results - Entasis Therapeutics Holdings reported initial preliminary results from the first-in-human Phase 1 clinical trial of its novel, oral beta-lactamase inhibitor ETX0282. The Phase 1 trial is evaluating the safety, tolerability and pharmacokinetics of ETX0282 either alone or in combination with cefpodoxime proxetil, ETX0282CPDP, in healthy volunteers. The Company is developing ETX0282CPDP as an oral therapy for infections caused by multidrug-resistant Gram-negative pathogens, including ESBL-producing and carbapenem-resistant Enterobacteriaceae. This Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study of ETX0282 in healthy subjects and consists of several parts including: single-ascending dose, multiple-ascending dose, effect of food on absorption, and assessment of drug-drug interaction between ETX0282 and cefpodoxime proxetil. The trial has currently enrolled 79 healthy subjects with 61 subjects having received at least one oral dose of ETX0282 between 100mg - 800mg. In the Phase 1 trial, ETX0282 in a "powder in capsule" formulation was rapidly absorbed, and plasma concentrations of the beta-lactamase inhibitor were in the projected therapeutic range. There was no drug-drug interaction between ETX0282 and cefpodoxime proxetil. When administered with a high fat meal, ETX0282 demonstrated similar overall exposures as compared to fasting subjects, but with a modified pharmacokinetic profile including decreased peak concentrations. ETX0282 was generally well tolerated either alone or in combination with cefpodoxime proxetil, with no serious adverse events reported. While eight subjects reported mild-to-moderate, transient emesis, none of the volunteers who received ETX0282 with a high fat meal reported emesis. Additional studies are planned to further investigate the potential correlation between absorption profile and emesis and to formulate ETX0282 for further clinical development.

08:02 EDT Byline Bancorp appoints Donald Gibson Jr. as General Counsel - Byline Bancorp announced that Donald Gibson Jr. has joined the company as Executive Vice President and General Counsel. Gibson joins Byline from MB Financial Bank, N.A., where he served as General Counsel since 2014.

07:56 EDT Veritas Farms launches hemp oil topical products in Kroger - Veritas Farms is pleased to announce that its topical products will be featured nationwide in 945 Kroger Family of Stores, including banners Kroger, Dillons, Fry's, Fred Meyer, King Soopers, Mariano's, Pick 'n Save, QFC and Smith's, across 17 states. Veritas Farms full spectrum hemp oil topical products include salves, moisturizing lotion, and lip balm

07:54 EDT Elbit Imaging announces update on agreement to sell Bangalore, India holdings - Elbit Imaging announced regarding the termination of the Joint Development Agreementand the Term Sheet between Elbit Plaza India Real Estate Holdings Limited and the purchaser regarding a 74.7 acre plot in Chennai, India held by an SPV subsidiary of EPI, a transaction with total consideration of INR 108 crores, that the parties have signed a share purchase agreement according to which: The Purchaser has paid a deposit of INR 5 crores in order to provide the Purchaser with an additional six months to complete the closing, which may be extended by another month upon payment by the Purchaser of an additional deposit of INR of 5 crores. As of this date, the Purchaser has deposited a total of INR 15 crores. If the Purchaser is unable to complete the closing within the aforesaid time periods, then the parties will mutually appoint an international real estate consulting firm for the purpose of identifying a third-party buyer within a period of six months. If the Purchaser is unable to complete the closing and no third-party buyer is found within the aforesaid time periods, both the JDA and SPA shall be terminated, subject to the Purchaser receiving the Deposits. However, the Purchaser will not be entitled to reimbursement of expenses incurred by it under the JDA. Any final price received from a third-party buyer above the Consideration will be shared 67% by the Purchaser and 33% by EPI. The Consideration is subject to adjustment with respect to the Deposits and the existing cash in the SPV. The Consideration will be remitted in Euro at the base rate already agreed upon by the parties. Foreign exchange loss arising due to change in conversion rate from INR to euro will be borne by the Purchaser and gain will be credited to the account of EPI. The parties withdraw the arbitration proceedings and other notices. At this stage, there is no certainty that the SPA closing will occur.

07:49 EDT Aemetis India plant achieves $4M monthly domestic biodiesel revenue - Aemetis announced that its Universal Biofuels India subsidiary achieved record domestic biodiesel revenues in May as shipments commenced under the previously announced $23M biodiesel supply contract to the three government-owned Oil Marketing Companies. The Aemetis biodiesel plant in India recently completed the installation and commissioning of a pretreatment plant and related utilities upgrades to convert lower cost, waste feedstocks into high quality distilled biodiesel to supply the approximately 25 billion gallon diesel market in India.

07:46 EDT Beyond Meat shares fall after Tyson Foods unveils first plant-based products - Shares of Beyond Meat (BYND) moved lower after Tyson Foods (TSN) introduced its first plant-based and blended products along with its new Raised & Rooted brand. "The initiative makes Tyson Foods the largest U.S. meat producer to enter the growing alternative protein segment with its own products," Tyson said this morning in a press release. The initial products under Raised & Rooted, which will launch this year, include plant-based nuggets as well as blended burgers made with a combination of beef and plants. Tyson's existing Aidells brand has also launched Aidells Whole Blends sausage and meatballs, made with chicken and plant-based ingredients. Tyson Foods expects to introduce additional alternative protein products "through multiple customers and sales channels." Following the news, shares of Beyond Meat are down 3%, or $4.57, to $137.40 while Tyson Foods is up 4%, or $3.11, to $85.00 in premarket trading.

07:42 EDT Accel Entertainment, TPG Pace enter business combination - Accel Entertainment announced that its shareholders have entered into a definitive business combination agreement with TPG Pace. The combined company will retain the Accel Entertainment name and will be a publicly listed company with an anticipated initial enterprise value of approximately $884M with de minimis leverage on its balance sheet. The transaction will help accelerate Accel's multi-state expansion plans. Operating more than 8,000 live slot machines in over 1,700 locations, Accel is the largest video gaming terminal operator in the United States on an EBITDA basis. TPG Pace expects Accel to generate more than $100M of Adjusted EBITDA in 2020. Accel has contractual agreements representing more than $3B of revenue with its local operating partners, with an average remaining contract life of 7.5 years. Accel's management team, led by co-Founder and CEO Andy Rubenstein, will continue to lead the company following the close of the transaction. In addition, TPG Pace announced that it has raised $45M in a private placement of common stock at $10.22 per share. The capital commitment is coming from the management team of TPG Pace, other partners of TPG, certain institutional investors as well as other senior industry executives from TPG's network. The transaction will be effected pursuant to the transaction agreement entered into by and among TPG Pace Holdings and the shareholders of Accel. Immediately prior to the consummation of the transaction, additional investors, including affiliates of TPG Pace, will purchase ordinary shares of TPG Pace in a $45M private placement. After giving effect to any redemptions by the public stockholders of TPG Pace, the combined balance of the cash held in TPG Pace's trust account and proceeds from the private placement of approximately $500M, will be used to pay existing Accel shareholders and transaction expenses, with the remaining cash on the balance sheet to be used to repay existing debt or for accretive capital deployment. Following the consummation of the transaction, TPG Pace will be renamed Accel Entertainment and its shares will remain listed on the New York Stock Exchange and trade using the ticker (ACEL). The consideration payable to the Accel shareholders will consist of common stock of TPG Pace and warrants to purchase common stock of TPG Pace. Accel's founders and management team are rolling at least 80% of their current Accel stake into the newly formed company. TPG Pace's sponsor will retain 7.3M founder shares and approximately 4.9M private placement warrants, as well as 2M earnout shares exercisable for TPG Pace common shares. In addition, Accel shareholders who roll in excess of 30% of their shares will be entitled to their pro rata portion of 2.4M warrants and 3M earnout shares exercisable for TPG Pace common shares. The earnout shares will be exercisable upon the achievement of certain EBITDA or stock price thresholds of TPG Pace. In addition, TPG Pace's sponsor will contribute 500,000 of its shares to a foundation created for charitable efforts in the communities in which Accel operates, or anticipates operating. The transaction has been executed by a majority of Accel's shareholders with the support of the board of directors of Accel and approved by the board of directors TPG Pace. The transaction is expected to close in late Q3, subject to the receipt of certain regulatory approvals and the approval of the transaction by a majority of the shareholders of TPG Pace.

07:39 EDT Francesca's remains "on track" to achieve $15M in annualized savings

07:29 EDT Target says same-day delivery now available directly through Target.com - Target announced in a post to its corporate website that same-day delivery shopped by Shipt is now available directly through Target.com. "Guests can now get 65,000 items delivered to their door in as soon as an hour with an order placed directly on Target.com...Plus, for guests who want to try out Shipt's delivery service, they can sign up for a free four-week trial or have the option to pay a $9.99 delivery fee for each order on Target.com, giving guests the benefits of same-day delivery without having to commit to an annual membership," the post stated. Reference Link

07:15 EDT Orchestra BioMed, Terumo form strategic partnership for Virtue SEB device - Orchestra BioMed announced it has formed a global strategic partnership with Terumo Corporation for development and commercialization of Virtue Sirolimus-Eluting Balloon in the percutaneous coronary and peripheral interventions field. Virtue SEB is a non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus. In April, the U.S. Food and Drug Administration granted Virtue SEB Breakthrough Device Designation for treatment of coronary in-stent restenosis, which provides prioritized regulatory review for this challenging cardiovascular condition that represents more than 10% of total interventional coronary procedures and for which available treatment options are limited. In a prospective study of very challenging ISR patients, Virtue SEB demonstrated excellent angiographic results at six months as well as outstanding clinical outcomes out to three years. Orchestra BioMed plans to conduct a near-term U.S. registrational trial for ISR. Under the terms of the agreement, Terumo will make a one-time, up-front payment of $30 million and an equity commitment of $5M to Orchestra BioMed. Terumo will also make substantial future clinical and regulatory milestone payments to Orchestra BioMed. Terumo will also make a strong commitment to finance and execute a global clinical program in collaboration with Orchestra BioMed to gain regulatory approval for commercial sale of Virtue SEB in multiple markets and indications. Orchestra BioMed will share meaningfully in future commercial revenues of Virtue SEB through royalties and per unit payments as the exclusive supplier of the proprietary sustained-release sirolimus formulation used in Virtue SEB. Orchestra BioMed retains the rights to develop and license technology used in Virtue SEB for clinical applications outside of coronary and peripheral vascular interventions.

07:08 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals reported the grant of inducement awards to Scott Jones, EyePoint's newly appointed CCO and Said Saim, Ph.D., EyePoint's newly appointed CTO. The Compensation Committee of Eyepoint Pharmaceutical's Board of Directors granted to Mr. Jones stock options to purchase an aggregate of 350,000 shares of common stock and granted to Dr. Saim stock options to purchase an aggregate of 300,000 shares of common stock, as inducement awards material to each of them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to Mr. Jones have an exercise price of $1.47 per share, the closing price of EyePoint's common stock on Mr. Jones' grant date of June 10, 2019, and the stock options granted to Dr. Saim have an exercise price of $1.63 per share, the closing price of EyePoint's common stock on Dr. Saim's grant date of June 11, 2019. One-fourth of the shares underlying the options granted to Mr. Jones and Dr. Saim will vest on the one-year anniversary of their respective dates of grant and thereafter 1/48th of the shares underlying each of these options will vest monthly, such that the shares underlying the options granted to Mr. Jones and Dr. Saim will be fully vested on the fourth anniversary of their respective dates of grant, subject to the terms of each grant.

07:07 EDT Tonix Pharmaceuticals issued patent in China for formulation of TNX-102 SL - Tonix Pharmaceuticals announced that the China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1 to the Company on April 16, 2019. This patent, "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride," is directed to a unique eutectic that characterizes TNX-102 SL*, and claims pharmaceutical compositions containing that eutectic and methods of making those compositions. Tonix's proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for long-term daily use at bedtime and sublingual administration, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism. Marketed cyclobenzaprine drug products are limited to short-term use and indicated for oral ingestion, which results in significant liver metabolism. Sublingual TNX-102 SL has a different pharmacokinetic profile than marketed oral cyclobenzaprine drug products. TNX-102 SL is being developed as a treatment for three indications: posttraumatic stress disorder, fibromyalgia and agitation in Alzheimer's disease. Marketed oral cyclobenzaprine products are indicated for the relief of muscle spasm.

07:06 EDT McDermott awarded paraxylene technology contract in China - McDermott has been awarded a sizeable technology contract by Ningbo Union King Polyester Material for the technology license, process design engineering, and operator training services for a large-scale, grassroots 1,600 KTA paraxylene plant at Ningbo Union King's petrochemicals facility in Ningbo, China. McDermott defines a sizeable contract as between $1M and $50M. This award was reflected in McDermott's Q1 backlog.

07:03 EDT Hill International to provide technical assistance for infrastructure in Albania - Hill International announced it was selected by the European Union, as the leader of the consortium including Deloitte Albania and LDK Consultants, to provide Technical Assistance to strengthen the capacity for the overall planning, preparation, and implementation of infrastructure projects in Albania. This assignment is part of the IPA 2015 Action Program for Albania. The overall objective of the program is to strengthen the capacity and accountability of the State's administration of the design and implementation of sector programs and major infrastructure projects. Specifically, the scope includes assisting the State administration to maintain a standard investment prioritization methodology, including the process of selection, prioritization, assessment of viability and sustainability, and development of infrastructure projects. This includes the National Single Project Pipeline (NSPP) and Sector Single Project Pipelines. Furthermore, the program will enhance the State's capacity and training staff across Ministries and Agencies involved in feasibility assessments, planning, design, procurement, implementation, and monitoring of infrastructure projects.

06:58 EDT Tyson Foods launches alternative protein products and Raised & Rooted Brand - Tyson Foods introduced the company's first plant-based and blended products, along with its new Raised & Rooted brand. The initial products under this new brand, which will launch with several major retail customers this year, include plant-based nuggets as well as blended burgers made with a combination of beef and plants. In addition, the company's existing Aidells brand has launched Aidells Whole Blends sausage and meatballs, made with chicken and plant-based ingredients. Tyson Foods expects to introduce additional alternative protein products through multiple customers and sales channels.

06:49 EDT Xoma's gevokizumab used to dose first patient in cancer study by Novartis - Xoma (XOMA) announced that gevokizumab, an anti-IL1beta monoclonal antibody that Xoma discovered and initially developed, is now actively progressing in a Novartis (NVS) oncology development program. The antibody candidate is being evaluated to determine the appropriate dose, as well as preliminary safety and efficacy, in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer, and metastatic renal cell carcinoma. Recently the first patient was dosed with gevokizumab in the dose-finding portion of the study. Gevokizumab is an investigational compound. Efficacy and safety have not been established. There is no guarantee that gevokizumab will become commercially available.

06:33 EDT Regis sells 96 Supercuts salons to Moxie Management Group - Regis announced the sale and transfer of 96 of its California-based Supercuts salons to the Moxie Management Group, a portfolio company of a Spanos Barber Jesse & Co. - SBJ - managed fund. Supercuts expects to initiate a new marketing campaign during All Star Week, which is being held in Cleveland July 5-9.

06:03 EDT Cedar Fair to acquire two Texas water parks from Schlitterbahn for $261M - Cedar Fair has signed a definitive agreement to acquire two water parks and one resort in Texas - Schlitterbahn Waterpark and Resort New Braunfels and Schlitterbahn Waterpark Galveston for a cash purchase price of $261M, subject to certain working capital adjustments related to the timing of the closing. Additionally, Cedar Fair has the right to acquire a property located in Kansas City, Kansas, for a cash purchase price of $6M. In 2018, Cedar Fair entertained 25.9 million guests, reported $1.35B in annual net revenues and generated Adjusted EBITDA1 of $468M, or 35% Adjusted EBITDA margin. The two Texas water parks and the resort entertained 1.2 million guests in 2018 and generated annual revenues of approximately $68M. Cedar Fair expects the two Texas locations to achieve an Adjusted EBITDA margin in line with Cedar Fair's standalone results as management implements a number of growth and operational initiatives at the parks over the next two years. The transaction is expected to close during Q2. The company intends to finance the transaction through additional long-term borrowings.

06:02 EDT Ford expanding testing of self-driving Fusion Hybrid to Detroit - Ford is expanding testing of its third-generation self-driving Fusion Hybrid to Detroit, Argo AI President Peter Rander said. "Earlier this month, I had the chance to visit Detroit and see the Motor City from a new perspective when I stepped into the backseat of one of our self-driving test vehicles. Our new Ford Fusion Hybrid is a third-generation test vehicle that Argo AI is now deploying in collaboration with Ford in all five major cities we're operating in: Pittsburgh, Palo Alto, Miami, Washington, D.C., and now Detroit - where we're expanding our testing footprint in Michigan beyond Dearborn." He added: "Every city represents a unique opportunity to make our self-driving system smarter because of the exposure to different road infrastructure design, driving behavior and even traffic light placement. The collective knowledge we're gaining by operating in five very different locales is a big part of the reason why we're making great progress." He noted that the new cars are "equipped with a significantly upgraded sensor suite, including new sets of radar and cameras with higher resolution and higher dynamic range." Reference Link

05:30 EDT Discover extends merchant acceptance in Spain through agreement with Redsys - Redsys and Discover Global Network, the payments brand of Discover Financial Services, announced that they have signed an agreement that will extend merchant acceptance throughout Spain. "The agreement enables Discover to work with additional acquirers in the region in an effort to increase acceptance for Discover, Diners Club International, PULSE and affiliate network cards. The new agreement makes it possible for Discover to connect with more merchants in the country that are interested in accepting Discover Global Network cards through Discover acquirer relationships." Through Redsys, Discover has already signed agreements with two primary acquirers in Spain and is exploring additional relationships to increase acceptance even further.

05:23 EDT KKR to sell KCF Technologies to SKC for $1B - KKR announced that SK Group affiliate SKC will acquire a 100% equity stake in KCF Technologies from KKR for $1B. KKR made its investment in KCFT from its Asian Fund III. This transaction is subject to customary regulatory consents and approvals. Further details of the transaction are not disclosed.